Atlas Trials

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Clinical trial NCT05931328 · RECRUITING

Trial details

NCT number
NCT05931328
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
Start date
2022-10-15
Primary completion
2024-10-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.